Microsatellite genotyping reveals a signature in breast cancer exomes

• Published in: Breast cancer research and treatment Vol. 145; no. 3; pp. 791 - 798
• Main Authors: McIver, L. J., Fonville, N. C., Karunasena, E., Garner, H. R.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01-06-2014; Springer; Springer Nature B.V
• Subjects: Analysis; Breast cancer; Breast Neoplasms - genetics; Brief Report; Cancer; Cancer research; Cancer therapies; DNA; DNA, Neoplasm - genetics; Exome - genetics; Female; Gene Frequency; Genetic aspects; Genomics; Genotype; Genotype & phenotype; Health aspects; Humans; Male; Medicine; Medicine & Public Health; Microsatellite Instability; Microsatellite Repeats - genetics; Mutation; Oncology; Risk assessment; Microsatellite variation; Breast cancer risk assessment; Cancer genomics; The Cancer Genome Atlas
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-014-2908-8

Genomic instability at microsatellite loci is a hallmark of many cancers, including breast cancer. However, much of the genomic variation and many of the hereditary components responsible for breast cancer remain undetected. We hypothesized that variation at microsatellites could provide additional genomic markers for breast cancer risk assessment. A total of 1,345 germline and tumor DNA samples from individuals diagnosed with breast cancer, exome sequenced as part of The Cancer Genome Atlas, were analyzed for microsatellite variation. The comparison group for our analysis, representing healthy individuals, consisted of 249 females which were exome sequenced as part of the 1,000 Genomes Project. We applied our microsatellite-based genotyping pipeline to identify 55 microsatellite loci that can distinguish between the germline of individuals diagnosed with breast cancer and healthy individuals with a sensitivity of 88.4 % and a specificity of 77.1 %. Further, we identified additional microsatellite loci that are potentially useful for distinguishing between breast cancer subtypes, revealing a possible fifth subtype. These findings are of clinical interest as possible risk diagnostics and reveal genes that may be of potential therapeutic value, including genes previously not associated with breast cancer.